Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of mRNA-1273.351 in Naïve and Previously Vaccinated Adults
NCT04785144Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mRNA-1273.351 in coronavirus disease 2019 (COVID-19) (10 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Medically-attended Adverse Events at 1 year, New-onset Chronic Medical Conditions at 1 year and 4 more. Started Mar 2021; status: completed.
02
Drugs
mRNA-1273.351
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04785144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785144.